A "one-size-fits-all" new class of drugs that targets a particular type of brain inflammation is showing early promise for the treatment of Alzheimer's disease, Parkinson's disease, multiple sclerosis and traumatic brain injury. A pre-clinical study due to be published this week in the Journal of Neuroscience shows one of the drugs stopped mice bred to have Alzheimer's from developing the full-blown disease...
More...
More...